Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, October 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Korn Maintained (BNTX) at Hold with Decreased Target to $110 on, Oct 17th, 2023
Matthew Korn of Morgan Stanley, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $116 to $110 on, Oct 17th, 2023.
Matthew has made no other calls on BNTX in the last 4 months.
There are 3 other peers that have a rating on BNTX. Out of the 3 peers that are also analyzing BNTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yifeng Liu of "HSBC" Downgraded from Strong Buy to Hold and Decreased Target to $111 on, Monday, October 16th, 2023
These are the ratings of the 2 analyists that currently disagree with Matthew
- Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $180 on, Monday, August 28th, 2023
- Rajesh Kumar of "HSBC" Initiated at Strong Buy and Held Target at $124 on, Friday, July 14th, 2023
